Apr 09,2019

Glytec Receives Another Patent Allowance for Therapy Advisor®

The company is expanding its software-as-a-medical-device platform to support the optimization of ALL diabetes medications. The United States Patent and Trademark Office has granted Glytec another patent allowance for systems and methods related to a product registered under the brand name, Therapy Advisor®. Currently under development, the new product will extend the company’s core competencies beyond insulin optimization to include oral, inhaled and non-insulin injectable diabetes medications.

PRODUCT
View Analyst & Ambassador Comments
Go to original news
Apr 09,2019

New OneTouch Reveal® Plus Mobile App Powered by Welldoc’s BlueStar® Technology Provides Evidence-Based In-App Coaching to Help Drive Better Diabetes Self-Management and Health Outcomes in Canada

LifeScan today introduced the OneTouch Reveal® Plus mobile app, which received Health Canada license and will soon be available to health benefit plans for adults 18 years and older living with diabetes. Powered by Welldoc’s BlueStar® technology – OneTouch Reveal® Plus will offer individualized, real-time coaching based on a patient’s specific treatment plan, from the same familiar brand as the #1 downloaded diabetes mobile app in Canada, the OneTouch Reveal® mobile app.1

PRODUCT

#mobile app

#coaching

View Analyst & Ambassador Comments
Go to original news
Apr 09,2019

Voluntis appoints Berkley Nelson as Chief Growth Officer

Voluntis, a company specializing in digital therapeutics, today announced that Berkley Nelson has joined the company as Chief Growth Officer and member of Voluntis’ Leadership Team. Berkley will head Voluntis’ commercial activities to develop new partnerships with payer and provider organizations in North America.

View Analyst & Ambassador Comments
Go to original news
Apr 10,2019

Brigter's Change in Management and Board of Directors.

The Nomination Committee of Brighter AB has proposed Truls Sjöstedt as new Chairperson of the Board and will endorse the proposal at the Annual General Meeting 2019. Truls is currently the company's CEO. The Board of Directors intends to appoint Henrik Norström, today COO, as CEO in connection with the Annual General Meeting on May 9.

View Analyst & Ambassador Comments
Go to original news
Apr 16,2019

The OneTouch Verio Reflect™ Blood Glucose Monitoring System (BGMS) with Blood Sugar Mentor™ Messages Coming Soon to Canada

LifeScan, a world leader in blood glucose monitoring, today announced the new OneTouch Verio Reflect™ system received Health Canada’s authorization for sale and will be available in stores beginning mid‐May 2019. The only blood glucose monitoring system with the new Blood Sugar Mentor™ messages, this new device analyzes and informs patients of blood glucose trends and potential causes and provides them with personalized guidance that could help them understand what causes their hypo or hyperglycemia.

PRODUCT

#bgm

View Analyst & Ambassador Comments
Go to original news
Apr 16,2019

Tandem Diabetes Care to Announce First Quarter 2019 Financial Results on April 30, 2019

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2019 results after the financial markets close on Tuesday, April 30, 2019. The Company will hold a conference call and simultaneous webcast on the same day at 4:30pm Eastern Time (1:30pm Pacific Time), to discuss its first quarter 2019 financial and operating results.

View Analyst & Ambassador Comments
Go to original news
Apr 17,2019

ABBOTT REPORTS FIRST-QUARTER 2019 RESULTS

In Diabetes Care, sales increased 34.4 percent on a reported basis and 42.0 percent on an organic basis in the first quarter. Sales growth in the quarter was led by FreeStyle® Libre®, Abbott's revolutionary continuous glucose monitoring system, with worldwide sales of $379 million, an increase of 70.2 percent on a reported basis and 80.1 percent on an organic basis versus the prior year. During the quarter, Abbott released real-world data from nearly 500,000 users that shows higher rates of scanning with its FreeStyle Libre system improves glucose control for people living with diabetes.

View Analyst & Ambassador Comments
Go to original news
Apr 18,2019

Nemaura Announces Addition of New Predictive Alert Functionality to SugarBEAT®

Nemaura Medical, Inc. (NASDAQ: NMRD), a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has incorporated new predictive alert functionality into SugarBEAT®.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 23,2019

Nemaura Announces Successful Completion of Summative Human Factors Usability Study for SugarBEAT®

Nemaura Medical, Inc., a medical technology company focused on the development of SugarBEAT® as a non-invasive, affordable and flexible Continuous Glucose Monitor (CGM) for use by diabetics and pre-diabetics, today announced that it has successfully completed two summative human factors usability studies for SugarBEAT®. The usability studies were conducted according to the U.S. Food and Drug Administration (FDA) guidance on ‘Applying Human Factors and Engineering to Medical Devices,’ in preparation for submission of its medical device application to the FDA for SugarBEAT®.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 25,2019

Brighter publishes annual report for 2018.

Brighter announces that the annual report for 2018 is available on the company's website. Company's operating income amounted to SEK 26,073,000 (32,825) of which capitalized work for own bill amounted to SEK 25,021,000 (29,754).

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES